Fezz, this is a very interesting as it relates to Car-T with Yescarta and Mayo Clinic Patients. It does not mention Lenzilumab, and the patients being studied are not from the Zuma-19 Collaboration with Kite/Gilead with Lenzilumab & Yeascarta, but it is discussing the occurrence of Cytokine Release Syndrome and Neurotoxicity in response to treatment with Yescarta. Have you had a chance to read this, and if so do you have an opinion on what is being discussed?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.